3billion Targets US Market: Will a ₩4.2B Acquisition Fuel Growth?

3billion Sets Sights on US Expansion with ₩4.2B Investment

On September 9, 2025, 3billion announced the acquisition of 3billion US, Inc. for ₩4.2 billion. This investment, representing 14.75% of 3billion’s capital, is a strategic move to penetrate the US market. 3billion US, Inc. specializes in WES/WGS-based rare disease genetic testing, creating potential synergy with 3billion’s existing business.

Implications of US Market Entry for 3billion

• Positive Impacts:
  • Direct access to the US market, enhancing customer reach and potential market share growth.
  • Potential for increased revenue and profitability, with synergy through the SaaS model.
  • Strengthened global competitiveness and momentum for further international expansion.
  • Enhanced core business capabilities and portfolio diversification.
• Negative Impacts and Risks:
  • Short-term liquidity constraints due to the ₩4.2 billion cash outflow.
  • Uncertainties and risks associated with US market entry and the post-merger integration (PMI) process.
  • Potential profit fluctuations due to USD/KRW exchange rate volatility.
  • Uncertainty regarding the profitability of the US subsidiary.

Key Checkpoints for Investors

While this acquisition is viewed as a positive event that enhances 3billion’s growth potential, investors should closely monitor the following:

• The company’s cash flow management.
• The progress and performance of the US subsidiary’s PMI.
• Future trends in earnings improvement.

This analysis is not investment advice, and investment decisions are the sole responsibility of the investor.